Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mitoxantrone
Drug ID BADD_D01480
Description An anthracenedione-derived antineoplastic agent.
Indications and Usage For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Marketing Status Prescription; Discontinued
ATC Code L01DB07
DrugBank ID DB01204
KEGG ID D08224
MeSH ID D008942
PubChem ID 4212
TTD Drug ID D0R3JB
NDC Product Code 61703-343; 0703-4685; 0703-4686; 0703-4680
Synonyms Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone
Chemical Information
Molecular Formula C22H28N4O6
CAS Registry Number 65271-80-9
SMILES C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ApoptosisG1/S-specific cyclin-D1P24385T123558219202; 1450413; 9816016; 7683227; 8096557; 8243566; 8260751; 7915211; 9581849
ApoptosisTranscription factor JunP05412T690858219202; 1450413; 9816016; 7683227; 8096557; 8243566; 8260751; 7915211; 9581849
Cytogenetic investigationsDNA topoisomerase 1P11387T098261997159; 1649059; 1333822; 1540962; 1596908; 1330289; 8382551; 2168279; 2168281; 1319346; 11062742; 1374671; 1646393; 7882360; 1322239; 7688316; 1659821; 8383887; 8144400; 1698546
Toxicity to various agentsEpoxide hydrolase 1P07099Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neutropenia01.02.03.0040.001332%Not Available
Non-Hodgkin's lymphoma16.35.01.001; 01.17.01.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Onycholysis23.02.05.004--Not Available
Pain08.01.08.004--
Pancytopenia01.03.03.0030.000799%Not Available
Paraesthesia17.02.06.005--
Pathogen resistance11.01.08.049--Not Available
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Phlebitis24.05.03.001; 12.02.01.002--
Platelet count13.01.04.011--Not Available
Platelet count abnormal13.01.04.005--Not Available
Platelet count decreased13.01.04.001--
Pneumonia22.07.01.003; 11.01.09.0030.000208%Not Available
Proteinuria20.02.01.011--
Pulmonary oedema22.01.03.003; 02.05.02.0030.000533%
Pyrexia08.05.02.0030.001066%
Rash23.03.13.001--Not Available
Renal disorder20.01.02.002--Not Available
Renal failure20.01.03.005--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Second primary malignancy16.16.01.0140.000139%
Seizure17.12.03.001--
Sepsis11.01.11.003--
Septic shock24.06.02.011; 11.01.11.0040.000139%Not Available
Shock24.06.02.002--Not Available
Sinus bradycardia02.03.03.009--
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages